Cargando…

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

Detalles Bibliográficos
Autores principales:	Tran, Thai Hoa, Nguyen, Jonathan V., Stecula, Adrian, Akutagawa, Jon, Moorman, Anthony V., Braun, Benjamin S., Sali, Andrej, Mullighan, Charles G., Shah, Neil P., Dai, Yunfeng, Devidas, Meenakshi, Roberts, Kathryn G., Smith, Catherine C., Loh, Mignon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327742/ https://www.ncbi.nlm.nih.gov/pubmed/33626861 http://dx.doi.org/10.3324/haematol.2020.261354

Ejemplares similares

Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis
por: Welsh, Seth J., et al.
Publicado: (2017)

Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib
por: Hassan, Mohammed, et al.
Publicado: (2019)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

伴EBF1-PDGFRB融合基因阳性急性淋巴细胞白血病2例报告并文献复习
Publicado: (2023)

Dasatinib/imatinib: Treatment failure: case report
Publicado: (2022)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

伴EBF1-PDGFRB融合基因的Ph样急性B淋巴细胞白血病一例报告并文献复习
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review
por: Wang, Zhe, et al.
Publicado: (2022)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
por: Sánchez-Ortega, Isabel, et al.
Publicado: (2016)

Characteristics of 681 Low Vision Patients in Korea
por: Kim, Jae Hoon, et al.
Publicado: (2010)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Recurrent PDGFRB mutations in unicentric Castleman disease
por: Li, Zhaoming, et al.
Publicado: (2019)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
por: Zeng, Jing, et al.
Publicado: (2017)

Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice
por: Hong, Yeon Hee, et al.
Publicado: (2020)

A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib
por: Borogovac, Azra, et al.
Publicado: (2021)

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement
por: Di Giacomo, Danika, et al.
Publicado: (2021)

Corneal Vascularization Associated With a Novel PDGFRB Variant
por: Gladkauskas, Titas, et al.
Publicado: (2023)

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)

The characteristics and outcomes of 681 severe cases with COVID-19 in China
por: Chen, Fang-fang, et al.
Publicado: (2020)

Borrelia burgdorferi DnaA and the Nucleoid-Associated Protein EbfC Coordinate Expression of the dnaX-ebfC Operon
por: Krusenstjerna, Andrew C., et al.
Publicado: (2022)

Laboratory findings and clinical outcomes of 681 COVID-19 patients with dyslipidemia requiring hospitalization
por: Liontos, A., et al.
Publicado: (2022)

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t(5;10)(q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene
por: Yamazaki, Miki, et al.
Publicado: (2019)

Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature
por: De Luca-Johnson, Javier, et al.
Publicado: (2016)

Sequence Analysis of the Nucleocapsid Protein Gene of Rat Coronavirus SDAV-681
por: Kunita, Satoshi, et al.
Publicado: (1993)

68.1 Physician Burnout Levels and the Effect of the COVID-19 Pandemic
por: Lockwood, Laura
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_33mcoaam5sfiv5954ltskt9ui0